Ranibizumab Control
Phase 3
AbbVieRanibizumab Control is one of 8 therapeutic programs targeting Neovascular Age-related Macular Degeneration. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
10 competitors in Neovascular Age-Related Macular Degeneration
#DrugCompanyPhaseTrials
1Lucentis
RochePhase 3
Lucentis
NovartisApproved
Eylea
RegeneronPhase 3
Avastin
BBio-Thera Solutions
Phase 3
Surabgene Lomparvovec (ABBV-RGX-314)
AbbViePhase 3
Ranibizumab Control
AbbViePhase 3
Diluent
SanofiPreclinical
SAR402663
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Neovascular Age-related Macular Degeneration1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Ranibizumab Control. EMBL-EBI & Wellcome Sanger Institute.
- [3]